Information Provided By:
Fly News Breaks for March 29, 2018
DPLO
Mar 29, 2018 | 09:04 EDT
Lake Street analyst Brooks O'Neil noted that drug price inflation is currently a popular "hot button" and healthcare "middlemen" are being pointed to as the key problem in the cost escalation. However, he sees Diplomat Pharmacy as a unique and attractive part of the solution, not part of the problem, and he believes the current misperception of the company and its business presents an "exceptional opportunity for investors." O'Neil affirmed his Buy rating and $35 price target on Diplomat shares.
News For DPLO From the Last 2 Days
There are no results for your query DPLO